(S)-Warfarin 7-hydroxylation and midazolam 1'-hydroxylation are among the preferred probe substrate reactions for CYP2C9 and CYP3A4/5, respectively. The impact of solvents on enzyme activity, kinetic parameters, and predicted in vivo hepatic clearance (Cl H ) associated with each reaction has not been evaluated. The effects of increasing concentrations (0.1-2% (v/v)) of six organic solvents (acetonitrile, methanol, ethanol, DMSO, acetone, isopropanol) were first tested on each reaction using human liver microsomes (HLMs), human intestinal microsomes (midazolam 1'-hydroxlation only), and recombinant enzymes. Across enzyme sources, relative to water, acetonitrile and methanol had the least inhibitory effect on (S)-warfarin 7-hydroxylation (0-58% and 9-96%, respectively); acetonitrile, methanol, and ethanol had the least inhibitory effect on midazolam 1'-hydroxylation (0-29%, 0-22%, and 0-20%, respectively). Using HLMs, both acetonitrile and methanol (0.1-2%) decreased the V max (32-60% and 24-65%, respectively), whereas methanol (2%) increased the K m (100%), of (S)-warfarin hydroxylation. (S)-Warfarin Cl H was underpredicted by 21-65% (acetonitrile) and 13-84% (methanol). Acetonitrile, methanol, and ethanol had minimal to modest impact on both the kinetics of midazolam 1'-hydroxylation (10-24%) and predicted midazolam Cl H (2-20%). In conclusion, either acetonitrile or methanol at ≤ 0.1% is recommended as the primary organic solvent for the (S)-warfarin 7-hydroxylation reaction; acetonitrile is preferred if higher solvent concentrations are required. Acetonitrile, methanol, and ethanol at ≤ 2% are recommended as primary organic solvents for the midazolam 1'-hydroxylation reaction. This information should facilitate optimization of experimental conditions and improve the interpretation and accuracy of in vitro-in vivo predictions involving these two preferred P450 probe substrate reactions.
INTRODUCTION
Organic solvents often are required to solubilize xenobiotics for the purpose of characterizing metabolic pathways and evaluating drug interaction liabilities in vitro. It has been recognized since at least the late 1960s that an organic solvent can modulate enzymatic activity. A study published in 1980 evaluated the effects of nine water-miscible organic solvents on different mixed-function oxidase activities, including benzo[a]pyrene hydroxylation, 7-ethyoxycoumarin O-deethylation, aminopyrine N-demethylation, p-nitroanisole O-demethylation, and aniline hydroxylation (Kawalek and Andrews, 1980) . Different solvents had different effects on a given reaction. Several of the substrates used are now known to be metabolized by one or more cytochrome P450 (P450) enzymes. In the late 1990s, the effects of different solvents on probe substrate reactions for a number of drug metabolizing P450s were examined (Draper et al., 1997; Chauret et al., 1998; Hickman et al., 1998; Busby et al., 1999; Tang et al., 2000) .
Scientists at the Food and Drug Administration subsequently compiled information from these latter reports to recommend assay conditions for in vitro drug interaction studies, in which any solvent causing ≤ 20% inhibition was considered acceptable (Yuan et al., 2002) . The recommendations highlighted a critical lack of information regarding solvent effects on (S)-warfarin 7-hydroxylation and midazolam 1'-hydroxylation, preferred probe reactions for CYP2C9 and CYP3A4/5, respectively. After a decade, insufficient information remains regarding selection of an organic solvent that will least confound interpretation of in vitro P450 inhibition studies involving either of these reactions. DMD #47134 5 CYP3A4 (Kenworthy et al., 1999; Schrag and Wienkers, 2001) . Similarly, CYP2C9 substrates have been shown to cluster into three distinct subgroups, one of which was represented by diclofenac, tolbutamide, and phenytoin; the remaining two subgroups were represented by (S)-warfarin and (S)-flurbiprofen (Kumar et al., 2006b) . Taken together, more than one probe substrate may be required to evaluate fully the inhibitory potential of a given xenobiotic on the activity of either enzyme. The recommendation of using more than one probe substrate for CYP2C9 and CYP3A4/5 underscores further the importance of filling the knowledge gap regarding solvent effects on the aforementioned (S)-warfarin and midazolam hydroxylation reactions.
The goal of the current work was to provide a comprehensive evaluation of the effects of organic solvents on CYP2C9-mediated (S)-warfarin 7-hydroxylation and CYP3A4/5-mediated midazolam 1'-hydroxylation. The first objective was to test the inhibitory potential of six commonly used solvents (acetonitrile, methanol, ethanol, DMSO, acetone, isopropanol) on each reaction using human intestinal and/or liver microsomes and recombinant P450 enzymes. The second objective was to examine the effects of the least inhibitory solvents on the kinetics of each reaction [(S)-warfarin 7-hydroxylation: acetonitrile, methanol; midazolam 1'-hydroxylation: acetonitrile, methanol, ethanol] using HLMs. The third objective was to assess the impact of the least inhibitory solvents on the predicted in vivo hepatic plasma clearance (Cl H ) of each substrate. This rigorous approach provided critical information for optimizing experimental conditions and for improving the interpretation and accuracy of in vitro-in vivo predictions involving (S)-warfarin and midazolam as probe substrates.
This article has not been copyedited and formatted. The final version may differ from this version. (Wang et al., 2007; Ngo et al., 2009) . The amount of 7-hydroxywarfarin or 1'-hydroxymidazolam formed in all enzyme sources was linear with respect to both incubation time and protein concentration (Wang et al., 2007; Ngo et al., 2009; Brantley et al., 2010) , the latter of which was optimized to mitigate non-specific binding concerns (data not shown). Determination of enzyme kinetics. (1) (2) where v represents velocity of metabolite formation, S represents nominal substrate concentration, S 50 represents substrate concentration corresponding to 50% of V max , and n represents the Hill coefficient. Goodness-of-fit was assessed from visual inspection of the observed versus predicted data, randomness of the residuals, Akaike information criteria, and
SEs of the parameter estimates.
Hepatic microsomal intrinsic clearance (Cl int ) was calculated as the ratio of V max to K m . The analogous term for substrates described by the Hill equation, maximum clearance, (Cl max ) (Houston and Galetin, 2008) , was calculated as follows:
Cl int or Cl max was scaled to whole-liver intrinsic clearance (Cl int,liver ) or whole-liver maximum intrinsic clearance (Cl max,liver ) using scaling factors of 45 mg microsomal protein/g liver and 20 g liver/kg body weight (Obach et al., 1997) . Predicted in vivo hepatic plasma clearance (Cl H ) was calculated using the well-stirred model:
where Q p represents hepatic plasma flow (11 ml/min/kg), assuming a hematocrit of 0.45 (Yang et al., 2007) ; f u represents the unbound fraction of substrate in plasma (0.01 and 0.02 for warfarin and midazolam, respectively) (O'Reilly, 1972; Thummel et al., 1996; Gorski et al., 1998; Obach, 1999) ; and f m represents the fraction of substrate clearance forming the metabolite (0.45
This article has not been copyedited and formatted. The final version may differ from this version. and 0.70 for 7-hydroxywarfarin and 1'-hydroxymidazolam, respectively) (Chan et al., 1994; Thummel et al., 1996; Gorski et al., 1998; Takahashi et al., 1999) .
Statistical Analysis. Data were analyzed statistically using SigmaStat (v3.5; Systat Software, Inc, San Jose, CA). If the amount of metabolite formed was below the limit of quantification, a value one-half the lowest calibration standard (0.04 pmol and 1.0 pmol for 7-hydroxywarfarin and 1'-hydroxymidazolam, respectively) was assigned. If the amount of metabolite formed was below the limit of detection, a value of zero was assigned.
Concentration-dependent inhibition by a given solvent in each enzyme source was evaluated by one-way analysis of variance (ANOVA); post hoc comparisons were made using Tukey's test when an overall difference resulted (p<0.05). Enzyme kinetic parameters are presented as estimates ± SEs. Between-concentration differences in enzyme kinetic parameters for a given solvent were evaluated by one-way ANOVA; post hoc comparisons were made using Tukey's test when an overall difference resulted (p<0.05).
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RESULTS

Initial testing of solvents on CYP2C9 and CYP3A4/5 probe substrate reactions. (S)-
Warfarin 7-hydroxylation. The tested solvents differentially inhibited (S)-warfarin 7-hydroxylation in HLMs and rCYP2C9s (Fig. 1) . Relative to water, acetonitrile and methanol at the lowest concentration examined (0.1%) demonstrated <20% inhibition in all enzyme sources except rCYP2C9*1 (24% and 21%, respectively). Acetone at 0.1% demonstrated <20% inhibition in HLMs and rCYP2C9*3 but not rCYP2C9*1 (32%) and rCYP2C9*2 (30%). The remaining solvents at 0.1% demonstrated >20% inhibition in all enzyme sources, from 23% by DMSO in rCYP2C9*3 to 58% by isopropanol in HLMs. Acetonitrile at 1% and 2% inhibited activity by 35-40% and 38-58%, respectively. The remaining solvents at 1% and 2% inhibited activity by >51% and >62%, respectively. The CYP2C9 inhibitor, sulfaphenazole, inhibited activity by >75% in all enzyme sources. Midazolam 1'-hydroxylation. The tested solvents differentially inhibited midazolam 1'-hydroxylation in HLMs, HIMs, and rCYP3As (Fig. 2) . Relative to water, methanol and ethanol had the least inhibitory effects, demonstrating <20% inhibition in all enzyme sources, and at all concentrations examined, except methanol at 2% in HIMs (22%). Acetonitrile demonstrated <20% inhibition in all enzyme sources except HLMs at the highest concentration tested (29%). DMSO, acetone, and isopropanol at 0.1% demonstrated <20% inhibition in all enzyme sources except DMSO in HIMs (29%) and acetone in rCYP3A4 (36%). These three solvents at higher concentrations demonstrated more variable and generally a greater extent of inhibition (23-83%) compared to methanol, ethanol, and acetonitrile. The inhibition profile of DMSO was distinct, showing a significant stepwise pattern. Acetone and isopropanol were the least consistent among enzyme sources; both solvents inhibited activity in HLMs and rCYP3A4 to a greater extent than activity in HIMs and rCYP3A5, with acetone showing particularly pronounced differential effects. The CYP3A inhibitor, ketoconazole, inhibited activity by ≥85% in all enzyme sources except rCYP3A5 (62%). (Fig. 1) , acetonitrile and methanol were selected for further evaluation. Eadie-Hofstee plots for both solvents at all concentrations examined suggested a unienzyme system (Fig. 3A and B) . The data were described best by the simple Michaelis-Menten equation (Eq. 1) (Fig. 3C and D) . Relative to water, acetonitrile had no significant effect on K m but decreased V max progressively, by 32-60%, with increasing concentrations (Table 1) (Fig. 2) , acetonitrile, methanol, and ethanol were selected for further evaluation. Eadie-Hofstee plots of all three solvents at all concentrations examined showed a characteristic "hook", indicative of autoactivation (Fig 4A, B , and C) (Houston, 2003) . The data were described best by the Hill equation (Eq. 2) (Fig. 4D , E, and F);
Hill coefficients ranged from 1.3-1.6 (SEs ≤ 0.10). Relative to water, all three solvents had no significant effect on either S 50 or V max regardless of concentration (Table 1) .
Effects of selected solvents on predicted hepatic plasma clearance of (S)-warfarin and midazolam. (S)-Warfarin. Relative to water, acetonitrile at 0.1% had a modest effect (21% decrease) on predicted Cl H , whereas the higher concentrations decreased predicted Cl H by 52-65% (Table 1) . Similar to acetonitrile, methanol at 0.1% had a modest effect (13% decrease) on predicted Cl H , whereas the higher concentrations decreased predicted Cl H by 58-84% (Table 1) .
Midazolam. Relative to water, all three solvents (acetonitrile, methanol, ethanol) at all concentrations examined had a negligible to modest effect (≤20%) on predicted Cl H (Table 1) .
DISCUSSION
The potential for organic solvents to modulate in vitro catalytic activity of drug metabolizing enzymes has been recognized for decades. Such enzymes include CYP2C9 and CYP3A4/5, which, combined, are involved in the oxidative metabolism of more than 50% of marketed drugs (Wienkers and Heath, 2005; Zanger et al., 2008) . In addition, more than one probe substrate has been recommended for drug interaction studies involving either enzyme (Kenworthy et al., 1999; Kumar et al., 2006b ). Despite these observations and recommendations, a lack of comprehensive information remains regarding selection of an optimal organic solvent for one of the preferred probe substrate reactions for each enzyme, specifically (S)-warfarin 7-hydroxylation (CYP2C9) and midazolam 1'-hydroxylation (CYP3A4/5). This deficiency has been addressed in the current evaluation of the effects of common solvents on each reaction in HLMs and/or HIMs and rCYPs.
As anticipated, different solvents differentially inhibited both probe substrate reactions. Initial testing showed that the effect of a given solvent varied with concentration and enzyme source.
An ideal solvent should have no inhibitory effect on enzyme activity. However, because solubility limitations are commonplace for lipophilic molecules, 20% inhibition or less has been deemed acceptable (Yuan et al., 2002) . This criterion was used to assess effects of the various solvents.
Acetonitrile and methanol at the lowest concentration examined (0.1%) inhibited (S)-warfarin 7-hydroxylation by <20% in all enzyme sources except rCYP2C9*1 (24% and 21%, respectively). At the higher concentrations tested (1% and 2%), acetonitrile had the least inhibitory effect, ranging from 35-40% and 38-58%, respectively. Previous studies examining effects of multiple solvents on CYP2C9 activity, all published before 2002, used tolbutamide or diclofenac as the probe substrate and a single enzyme source (HLMs, human hepatocytes, or recombinant enzyme) (Chauret et al., 1998; Hickman et al., 1998; Busby et al., 1999; Tang et al., 2000; Easterbrook et al., 2001 ). Consistent with current observations, acetonitrile had the 
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13 least inhibitory effect on both tolbutamide 4'-hydroxylation (HLMs, human hepatocytes) and diclofenac 4'-hydroxylation (rCYP2C9) at all tested concentrations, which ranged from 0.1% to 5%. However, the extent of inhibition (<5%) was typically much less than that of (S)-warfarin 7-hydroxylation, even at the lowest concentration examined. The increased sensitivity of (S)-warfarin compared to these other CYP2C9 substrates could reflect different experimental conditions and/or inherent differences in substrate access/binding to the enzyme active site, as discussed later.
Compared to (S)-warfarin 7-hydroxylation, midazolam 1'-hydroxylation was more resilient to the solvents. Methanol, ethanol, and acetonitrile demonstrated ≤ 20% inhibition in all enzyme sources except methanol at 2% in HIMs (22%) and acetonitrile at 2% in HLMs (29%). Most of the aforementioned pre-2002 studies examined solvent effects on CYP3A4/5 activity using testosterone as the probe substrate. Consistent with current observations, methanol (HLMs, human hepatocytes, rCYP3A4) and ethanol (rCYP3A4) at concentrations ≤ 2% had the least inhibitory effect on testosterone 6β-hydroxylation (<15% and <5%, respectively) (Chauret et al., 1998; Busby et al., 1999; Easterbrook et al., 2001 ). Acetonitrile at ≤ 1% tended to have a slightly greater effect, inhibiting activity in HLMs by up to 25% (Chauret et al., 1998; Busby et al., 1999; Easterbrook et al., 2001) . To the authors' knowledge, only one previous study examined effects of solvents on CYP3A4/5 activity using midazolam as the probe substrate (Iwase et al., 2006) . Using HLMs only, acetonitrile, methanol, and ethanol inhibited activity by <5%. These lower extents of inhibition compared with current observations may be attributable to the lower solvent concentrations tested (0.1-1%), higher substrate and microsomal protein concentrations (10 μ M and 0.5 mg/mL, respectively), and/or longer incubation time (10 min). Nevertheless, the relative resilience of both midazolam 1'-hydroxylation and testosterone 6β-hydroxylation to the tested solvents, along with the notion that midazolam and testosterone belong to different CYP3A4/5 substrate subgroups (Kenworthy et al., 1999) , was not unexpected given the promiscuous and flexible nature of CYP3A4 (Otyepka et al., 2012) . The solvents that showed the least inhibitory effects upon initial testing were evaluated further on the enzyme kinetics of each reaction in HLMs. Acetonitrile and methanol were selected for (S)-warfarin 7-hydroxylation; acetonitrile, methanol, and ethanol were selected for midazolam 1'-hydroxylation. Under control (water) conditions, K m (or S 50 ) and V max values were in close agreement with previous reports for both reactions (Rettie et al., 1988; Thummel et al., 1996; von Moltke et al., 1996; Kumar et al., 2006a; Isoherranen et al., 2008) , allowing generalization of results among laboratories. The K m of 7-hydroxywarfarin formation remained relatively constant (6-8 μ M), whereas V max decreased (11 to 4 pmol/mg/min), with increasing concentrations of acetonitrile and methanol (0.1-1%), suggesting non-competitive inhibition.
These observations are consistent with the effects of acetonitrile on the kinetics of the CYP2C9-mediated hydroxylation of celecoxib (Tang et al., 2000) . Only the highest concentration of methanol (2%) altered the K m of 7-hydroxywarfarin formation significantly (14 μ M). The increased K m , coupled with a decreased V max , suggests mixed-type inhibition, which has not been reported previously for any CYP2C9 probe reaction. In contrast to (S)-warfarin 7-hydroxylation, none of the tested solvents significantly altered the K m and V max of midazolam 1'-hydroxylation. These differential effects highlight further the differences between CYP2C9 and CYP3A4 in terms of flexibility and promiscuity, as well as the CYP2C9 substrate-dependent sensitivity to the tested solvents. values. Consistent with initial testing, acetonitrile or methanol at 0.1% did not impact the prediction of (S)-warfarin Cl H by more than 20%, whereas concentrations >1% underpredicted Cl H by more than 50%. Similar to (S)-warfarin, the predicted in vivo Cl H for midazolam under control conditions was within the range of observed values (5.5 vs. 5.3-7.6 ml/min/kg) (Thummel et al., 1996; Gorski et al., 1998; Tsunoda et al., 1999; Isoherranen et al., 2008) . Consistent with the lack of effect on S 50 and V max , the tested solvents at all concentrations had minimal to modest effect on Cl H , underpredicting by <20%. an additional (S)-warfarin molecule or other ligand, such as the inhibitor fluconazole (Williams et al., 2003) . This interaction has been shown to be essential for (S)-warfarin affinity and regioselectivity (Seifert et al., 2006) , as well as access to the heme moiety (Williams et al., 2003; Seifert et al., 2006) . Whether or not the tested solvents alter the kinetics of (S)-warfarin 7-hydroxylation via alterations in substrate binding and/or enzyme topology merit further investigation. This article has not been copyedited and formatted. The final version may differ from this version. 7.7 ± 0.9 5.9 ± 0.5 
